Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo

Cytotherapy

Volumn 15, Issue 8, 2013, Pages 986-998

  Song, Liujiang ^a,b,d   Kauss, M Ariel ^e   Kopin, Etana ^e   Chandra, Manasa ^e   Ul Hasan, Taihra ^e   Miller, Erin ^e   Jayandharan, Giridhara R ^b,f   Rivers, Angela E ^b,g   Aslanidi, George V ^b   Ling, Chen ^b   Li, Baozheng ^b   Ma, Wenqin ^b   Li, Xiaomiao ^b   Andino, Lourdes M ^b   Zhong, Li ^b,h   Tarantal, Alice F ⁱ   Yoder, Mervin C ^j   Wong, Kamehameha K ^e   Tan, Mengqun ^a,d   Chatterjee, Saswati ^e   Srivastava, Arun ^b,c   more..

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d Shenzhen Institute of Xiangya Biomedicine   (China)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f CHRISTIAN MEDICAL COLLEGE   (India)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

AAV vectors; Gene expression; Gene transfer; Hematopoietic stem cells

Indexed keywords

AMINO ACID; CD34 ANTIGEN; TYROSINE; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS TYPE 1; ADENO ASSOCIATED VIRUS TYPE 6; AMINO ACID ANALYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL FUNCTION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACACA FASCICULARIS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; RESIDUE ANALYSIS; SIGNAL TRANSDUCTION; VIRUS CAPSID; VIRUS ENTRY; XENOGRAFT; ANIMAL; C57BL MOUSE; CELL LINE; DEPENDOPARVOVIRUS; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; HEK293 CELL LINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; K562 CELL LINE; MALE; METABOLISM; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE;

MIRIDAE;

ANIMALS; ANTIGENS, CD34; CELL LINE; DEPENDOVIRUS; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; K562 CELLS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; TRANSDUCTION, GENETIC;

EID: 84892967754     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.04.003     Document Type: Article

References (40)

1. Cavazzana-Calvo M., Payen E., Negre O., Wang G., Hehir K., Fusil F., et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467:318-322.
2. Mueller C., Flotte T.R. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008, 15:858-863.
3. Mingozzi F., High K.A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011, 12:341-355.
4. Zhou S.Z., Cooper S., Kang L.Y., Ruggieri L., Heimfeld S., Srivastava A., et al. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. JExp Med 1994, 179:1867-1875.
5. Goodman S., Xiao X., Donahue R.E., Moulton A., Miller J., Walsh C., et al. Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood 1994, 84:1492-1500.
6. Fisher-Adams G., Wong K.K., Podsakoff G., Forman S.J., Chatterjee S. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood 1996, 88:492-504.
7. Chatterjee S., Li W., Wong C.A., Fisher-Adams G., Lu D., Guha M., et al. Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood 1999, 93:1882-1894.
8. Tian J., Wang F., Xue J.F., Zhao F., Song L.J., Tan M.Q. Recombinant AAV2-mediated beta-globin expression in human fetal hematopoietic cells from the aborted fetuses with beta-thalassemia major. Int J Hematol 2011, 93:691-699.
9. Paz H., Wong C.A., Li W., Santat L., Wong K.K., Chatterjee S. Quiescent subpopulations of human CD34-positive hematopoietic stem cells are preferred targets for stable recombinant adeno-associated virus type 2 transduction. Hum Gene Ther 2007, 18:614-626.
10. Nathwani A.C., Hanawa H., Vandergriff J., Kelly P., Vanin E.F., Nienhuis A.W. Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. Gene Ther 2000, 7:183-195.
11. Malik P., McQuiston S.A., Yu X.J., Pepper K.A., Krall W.J., Podsakoff G.M., et al. Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line. JVirol 1997, 71:1776-1783.
12. Alexander I.E., Russell D.W., Miller A.D. Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results. Hum Gene Ther 1997, 8:1911-1920.
13. Srivastava A. Obstacles to human hematopoietic stem cell transduction by recombinant adeno-associated virus 2 vectors. JCell Biochem 2002, 38:39-45.
14. Srivastava A. Hematopoietic stem cell transduction by recombinant adeno-associated virus vectors: problems and solutions. Hum Gene Ther 2005, 16:792-798.
15. Handa A., Muramatsu S., Qiu J., Mizukami H., Brown K.E. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. JGen Virol 2000, 81(Pt 8):2077-2084.
16. Schuhmann N.K., Pozzoli O., Sallach J., Huber A., Avitabile D., Perabo L., et al. Gene transfer intohuman cord blood-derived CD34(+) cells by adeno-associated viral vectors. Exp Hematol 2010, 38:707-717.
17. Veldwijk M.R., Sellner L., Stiefelhagen M., Kleinschmidt J.A., Laufs S., Topaly J., et al. Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34(+) peripheral blood progenitor cells. Cytotherapy 2010, 12:107-112.
18. Zhong L., Li W., Li Y., Zhao W., Wu J., Li B., et al. Evaluation of primitive murine hematopoietic stem and progenitor cell transduction in vitro and in vivo by recombinant adeno-associated virus vector serotypes 1 through 5. Hum Gene Ther 2006, 17:321-333.
19. Maina N., Han Z., Li X., Hu Z., Zhong L., Bischof D., et al. Recombinant self-complementary adeno-associated virus serotype vector-mediated hematopoietic stem cell transduction and lineage-restricted, long-term transgene expression in a murine serial bone marrow transplantation model. Hum Gene Ther 2008, 19:376-383.
20. Zhong L., Li B., Mah C.S., Govindasamy L., Agbandje-McKenna M., Cooper M., et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008, 105:7827-7832.
21. Kauss M.A., Smith L.J., Zhong L., Srivastava A., Wong K.K., Chatterjee S. Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2. Hum Gene Ther 2010, 21:1129-1136.
22. Cheng B., Ling C., Dai Y., Lu Y., Glushakova L.G., Gee S.W., et al. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther 2012, 19:375-384.
23. Qiao C., Zhang W., Yuan Z., Shin J.H., Li J., Jayandharan G.R., et al. Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 2010, 21:1343-1348.
24. Ussher J.E., Taylor J.A. Optimized transduction of human monocyte-derived dendritic cells by recombinant adeno-associated virus serotype 6. Hum Gene Ther 2010, 21:1675-1686.
25. Dalkara D., Byrne L.C., Lee T., Hoffmann N.V., Schaffer D.V., Flannery JG. Enhanced gene delivery tothe neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther 2012, 19:176-181.
26. Xiao X., Li J., Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. JVirol 1998, 72:2224-2232.
27. Lee C.C., Fletcher M.D., Tarantal A.F. Effect of age on the frequency, cell cycle, and lineage maturation of rhesus monkey (Macaca mulatta) CD34+ and hematopoietic progenitor cells. Pediatr Res 2005, 58:315-322.
28. Cearley C.N., Wolfe J.H. Asingle injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. JNeurosci 2007, 27:9928-9940.
29. Santat L., Paz H., Wong C., Li L., Macer J., Forman S., et al. Recombinant AAV2 transduction of primitive human hematopoietic stem cells capable of serial engraftment in immune-deficient mice. Proc Natl Acad Sci U S A 2005, 102:11053-11058.
30. Schimmenti S., Boesen J., Claassen E.A., Valerio D., Einerhand M.P. Long-term genetic modification of rhesus monkey hematopoietic cells following transplantation of adenoassociated virus vector-transduced CD34+ cells. Hum Gene Ther 1998, 9:2727-2734.
31. Ponnazhagan S., Mukherjee P., Wang X.S., Qing K., Kube D.M., Mah C., et al. Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. JVirol 1997, 71:8262-8267.
32. Weller M.L., Amornphimoltham P., Schmidt M., Wilson P.A., Gutkind J.S., Chiorini J.A. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med 2010, 16:662-664.
33. Allen H., Hsuan J., Clark S., Maziarz R., Waterfield M.D., Flavell R.A. Expression of epidermal-growth-factor receptor in the K562 cell line by transfection: altered receptor biochemistry. Biochem J 1990, 271:785-790.
34. Denard J., Beley C., Kotin R., Lai-Kuen R., Blot S., Leh H., et al. Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. JVirol 2012, 86:6620-6631.
35. Xiao W., Warrington K.H., Hearing P., Hearing P., Hughes J., Muzyczka N. Adenovirus-facilitated nuclear translocation of adeno-associated virus type2. JVirol 2002, 76:11505-11517.
36. Xiao P.J., Samulski R.J. Cytoplasmic trafficking, endosomal escape, and peri-nuclear accumulation of AAV2 particles are facilitated by microtubule network. JVirol 2012, 86:10462-10473.
37. Markusic D.M., Herzog R.W., Aslanidi G.V., Hoffman B.E., Li B., Li M., et al. High-efficiency transduction and correction of murine hemophilia Busing AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther 2010, 18:2048-2056.
38. Aslanidi G.V., Rivers A.E., Ortiz L., Govindasamy L., Ling C., Jayandharan G.R., et al. High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors. Vaccine 2012, 30:3908-3917.
39. Aslanidi G.V., Rivers A.E., Ortiz L., Song L., Govindasamy L., Tan M., et al. Optimization of recombinant adeno-associated virus 2 (AAV2) vectors for gene therapy: the final threshold?. PloS One 2013, 8:e59142.
40. Song L., Li X., Jayandharan G.R., Wang Y., Aslanidi G.V., Ling C., et al. High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo. PloS One 2013, 8:e58757.